Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2
Hear from experts Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, as they answer audience questions from the second in a series of live CCO Webinars on optimizing BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL).
Decera Clinical Education Oncology Podcast · Jeff P. Sharman MD, Danielle M. Brander MD, Nicole Lamanna MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:
- Rechallenging patients with venetoclax and BTK inhibitors
- Mechanism by which BTK inhibitors may reduce infusion reactions
- Risk of secondary malignancies with BTK inhibition
- Different cytogenetic findings and adverse event risk
Presenters:
Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon
Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies
& Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina
Nicole Lamanna, MD
Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.